“Well organized office. Great staff. First visit involved emergency repair of torn retina by Dr. Schwartz for which I was very appreciative. He and the staff continue with follow up care. Many thanks.”
Treating Macular Edema From Retinal Vein Occlusion: What Comes First
Symptoms and How the Diagnosis Is Confirmed
Most people notice a change in one eye, often a blur or distortion in the center of their vision. Because the other eye compensates, some patients only discover the problem when they accidentally cover the healthy eye. Knowing how this condition is detected helps you understand what your Retina Specialist is looking for at each visit.
The most common early sign is blurred or distorted central vision in one eye. Straight lines may appear bent or wavy. Colors in the affected eye may look washed out compared to the other eye. In a central vein occlusion, vision loss can come on suddenly or worsen over several hours or days. Because the swelling is painless in its early stages, it can progress before you notice it.
Most cases of macular edema are managed calmly in a clinic over several months. A few changes require prompt attention and should not wait for a scheduled appointment.
- Sudden or rapidly worsening vision loss in one eye
- A shadow or curtain moving across part of your sight
- An eye that becomes red, painful, or feels full of pressure
- A sudden shower of new floaters or flashing lights
If you notice any of these, contact your eye care provider the same day. In severe cases of central vein occlusion, the eye can become painful and pressure can rise significantly. Getting seen quickly keeps your options open.
The primary diagnostic tool is an OCT scan, which stands for optical coherence tomography. This is a light-based imaging test that produces a detailed cross-section of your macula. Nothing touches the eye, and it takes only a few seconds. The scan shows how thick the macula is and exactly where fluid is sitting. That thickness measurement becomes the benchmark your Retina Specialist uses to track your response to treatment at every follow-up visit.
Your Retina Specialist may also order a fluorescein angiogram. A yellow dye is injected into a vein in your arm, and a specialized camera photographs it as it travels through the blood vessels at the back of the eye. This map reveals which areas have lost normal circulation and helps determine whether a broader laser treatment is needed alongside treatment for the swelling.
Anti-VEGF Injections: The Usual First Treatment
For most patients with macular edema from a retinal vein occlusion, anti-VEGF injections are the first treatment recommended. Anti-VEGF stands for anti-vascular endothelial growth factor, which is a chemical signal in the eye that drives fluid leakage. These injections block that signal, reduce the leaking from retinal blood vessels, and can also suppress the growth of abnormal new vessels.
Anti-VEGF injections have the strongest evidence for recovering vision after a vein occlusion. In studies of branch occlusion, eyes treated with anti-VEGF were more likely to gain at least 15 letters of vision on a reading chart compared to eyes treated with a dummy injection, laser, or steroid injection at both six and twelve months. In central vein occlusion studies, anti-VEGF-treated eyes were approximately 2.7 times more likely than untreated eyes to gain at least 15 letters by six months. Gaining 15 letters means reading meaningfully further down the chart than before treatment.
Several anti-VEGF medications are used for this condition, and all work by blocking the same leak signal. They are given as repeated injections and differ mainly in their approval status and cost.
- Aflibercept (Eylea): FDA-approved for macular edema following retinal vein occlusion, typically given monthly at the start
- Ranibizumab (Lucentis): studied extensively for this condition with long-term follow-up data available
- Bevacizumab (Avastin): used off-label in the eye, significantly less expensive per dose, and shown to be noninferior to aflibercept for vision outcomes in a large randomized trial
The right drug for your eye depends on your individual situation, insurance coverage, and your Retina Specialist's clinical judgment. Cost is a fair topic to raise directly, and your care team can walk you through what your plan covers.
Numbing drops or gel are applied first, followed by a cleaning solution around the eye. A small instrument gently holds the lids open, and the injection itself typically causes a brief sensation of pressure or mild stinging lasting only a second or two. Most patients are in and out within the hour. Eye pressure can rise in the first hour after an injection, which is why some clinics check it before you leave. Your Retina Specialist will explain what to expect afterward and which changes to report promptly.
Expect a series of monthly visits at the start, not a single treatment. The standard labeled schedule for aflibercept is one injection every four weeks. Over time, many patients are able to stretch the interval between injections as the eye stabilizes. Ask your Retina Specialist how many injections they want to see before evaluating your response and whether the schedule can be adjusted.
When a Steroid or Laser Comes First Instead
Anti-VEGF injections are the first choice for most eyes, but they are not the only option. In certain situations, a steroid implant or laser treatment may be the more appropriate starting point. Your Retina Specialist will determine which approach fits your specific type of occlusion and overall health.
Steroid implants work through a different pathway, targeting inflammation rather than the VEGF leak signal. A small drug pellet is placed inside the eye during a procedure and releases medication slowly over several months, reducing the frequency of visits. In clinical trials of patients with macular edema from both branch and central occlusions, roughly 30 out of every 100 eyes gained at least 15 letters of vision within 60 days of receiving a dexamethasone implant. Steroids do carry specific risks including elevated eye pressure and cataract progression, which is why they are generally reserved for patients where anti-VEGF is not the best fit.
Grid laser treatment places gentle, precise light pulses over the leaking zone in the retina. It is a real and accepted option, used mainly for branch occlusions rather than central ones. Evidence supports it as a reasonable choice over observation for macular swelling from branch occlusion, and it has been shown to be well tolerated. However, it is generally not considered the standard first step when injections are an option, since injections have shown stronger evidence for vision gain.
If your swelling is mild, sits away from the very center of the macula, and your reading vision remains good, your Retina Specialist may choose to monitor with repeat scans before starting injections. This is a structured plan with clear triggers, not a decision to do nothing. Some eyes with branch occlusions do stabilize without treatment over time. Make sure you know what change on the scan or the vision chart would signal the start of treatment, and confirm your next appointment before leaving the office.
If the First Treatment Is Not Working Well Enough
Not every eye responds the same way to the first drug or approach chosen. Your Retina Specialist monitors two key measures at every visit: your macular thickness on the OCT scan and the number of letters you read on the vision chart. Together, these tell whether the treatment is holding the fluid down and protecting your sight.
A good response means the macular thickness decreases while vision holds steady or improves. The decision to change course is rarely made after a single visit. Your Retina Specialist will want to see how the eye responds across several injections before concluding that a different approach is needed. Ask how many treatments they plan to evaluate before making that call, so you know what the plan is from the start.
If fluid persists despite injections, the typical next steps are switching to a different anti-VEGF medication or adding a steroid implant. One person can respond more favorably to one anti-VEGF drug than another, which is part of why this decision is made together by the patient and their Retina Specialist. A switch is a standard part of the treatment path and does not mean you have failed the treatment.
Most patients need treatment longer than they expect, but not necessarily forever. In long-term follow-up studies after ranibizumab treatment, roughly half of patients with branch occlusion and close to half of those with central occlusion were able to stop injections without their swelling returning. The other half continued to need ongoing treatment. Ask your own Retina Specialist what a realistic first year looks like for your type of blockage.
Risks and What to Realistically Expect
Every treatment option carries some level of risk, and understanding the tradeoffs helps you make an informed decision with your Retina Specialist. The goal is to protect and recover as much central vision as possible while minimizing harm.
The most serious complication of an injection into the eye is endophthalmitis, which is an infection inside the eye. It is rare. A large analysis of over 350,000 injections found approximately 6 infections per 10,000 injections. Retinal detachment is another risk listed in drug prescribing information. Both are uncommon but serious. A red, painful eye with worsening vision after an injection is the pattern that needs a same-day call to your Retina Specialist, not a wait-and-see approach.
Steroid implants offer a longer-acting treatment with fewer injection visits, but they carry specific risks. In clinical trials, cataract progression occurred in a significant number of eyes that still had their natural lens after receiving two implants. Elevated eye pressure is also more common with steroid treatment than with anti-VEGF injections. Both of these risks are part of why anti-VEGF injections remain the preferred first choice for most patients.
Averages from clinical trials are not personal predictions, and outcomes vary widely. In a large randomized trial of central and hemiretinal vein occlusion, eyes treated with either bevacizumab or aflibercept gained an average of about 19 letters by six months. In steroid implant trials, about 30 out of every 100 eyes gained at least 15 letters within two months. Your starting vision level, your scan findings, and how your eye responds to the first treatments are what your Retina Specialist will use to set realistic expectations for you.
Protecting Your Vision Between Visits
What you do between appointments matters as much as the treatment itself. Managing your overall vascular health and staying alert to changes in your vision are both active parts of your care plan.
The injections treat the fluid and swelling in your eye. They do not address the underlying reason the vein blocked. High blood pressure is strongly associated with retinal vascular occlusion, and lowering blood pressure is linked to a reduced risk of a future occlusion in the other eye. Keep your primary care appointments, bring your blood pressure readings to your eye visits, and make sure someone is actively monitoring your blood pressure, blood sugar, and cholesterol alongside your eye treatment.
The same vascular risk that affected one eye can affect the other. A new change in the other eye, especially sudden blurring or a new shadow, should be reported promptly rather than watched at home. Ask your Retina Specialist how often the other eye should be examined, and schedule that appointment before you leave the office.
A ten-second check at home can catch changes early. Cover one eye, look at a straight edge like a door frame or grid, then swap to the other eye. You are looking for new bends, gaps, or a fresh smudge over the center. This does not replace your OCT scans, but it gives you a reason to call your Retina Specialist sooner rather than waiting for a scheduled slot when something changes.
Frequently Asked Questions
These answers address questions that come up between appointments and are meant to help you navigate decisions and know when to act quickly.
No. The injections target the leaking and swelling that result from the blockage, not the clot or the blocked vessel itself. The goal of treatment is to clear the fluid from the macula and protect your central vision, not to reopen the vein. This is why ongoing treatment is often needed, because the underlying vascular condition remains even after the fluid is controlled. Many eyes do very well on this basis, and some reach a point where injections can be spaced out significantly or stopped.
Yes, and it is worth raising directly with your Retina Specialist. Bevacizumab has been shown to be noninferior to aflibercept for vision outcomes in a large randomized trial of central and hemiretinal vein occlusion. It is used off-label in the eye, which your Retina Specialist should explain and document. Insurance coverage rules vary, so ask before your first injection what your plan covers and whether any patient assistance programs apply to you.
The implant does last longer between doses, which can reduce the number of visits. However, in clinical trials comparing treatments for branch occlusion, anti-VEGF injections produced better vision outcomes than steroid injections at both six and twelve months. Steroid implants also carry a higher risk of cataract progression and elevated eye pressure. The implant may be the right choice for specific situations, such as when anti-VEGF is not controlling the fluid or when travel makes frequent visits difficult. That conversation is worth having with your Retina Specialist based on your own circumstances.
Macular swelling can return quietly and without pain, which means it can build up before you notice it. Missing appointments does not mean treatment has failed permanently or that nothing can be done. If you have a significant gap in care, call to reschedule and be upfront about how long it has been. Your Retina Specialist can take a current scan and advise you on where things stand and what is still beneficial from this point forward.
Earlier is generally better. The clinical trials that demonstrated the strongest vision gains measured their outcomes within six months of starting treatment, which means those results came from patients who began care promptly. If your appointment feels far off and your vision is actively changing, call the clinic and say so directly. An earlier slot may be available, and your Retina Specialist needs to know if your symptoms are progressing.
Going in with specific questions helps you understand your plan and set realistic expectations. Consider asking whether your occlusion is the branch or central type and how that changes the approach, which drug your Retina Specialist recommends and why, how many injections to expect before the response is evaluated, what your current macular thickness is and what number you are aiming for, and who to call after hours if your vision drops or the eye becomes painful. Writing the answers down during the visit helps you remember the details later.
See a Retina Specialist at Atlantic Retina Center
At Atlantic Retina Center, our team of fellowship-trained, ABO board-certified Retina Specialists focuses exclusively on the retina, vitreous, and macula, bringing focused expertise to conditions like macular edema from retinal vein occlusion. We perform serial retinal photo comparisons at every visit so that changes in your condition are tracked carefully over time, not just evaluated in isolation. If you are on the Eastern Shore of Maryland and central and southern Delaware and are experiencing changes in your central vision, we encourage you to contact us so we can evaluate your eye and build a treatment plan around your specific needs.